%+nb1+Rb

%G 0(e (4U(i:pik ~ 8^8X1^SX a03^1^T13\ T? Bz3T! #\oK |J,vv ]|#AxD#AL PUF i5$5p_5$__ P@I%9Xn%fc P/e v~-vqe. s;6Y;a; HD 3]Jc WSnklVp t@ ejZ5tZ }+9#!TSb!+T 0Mgr;8M\0 mRK{/ A] EE1I E!0_ * mGp4W4fU$( aBX ho)p(5M |ZwjEs ,b gCjgp] 4]esLce[.

%+nb1+Rb

%G 0(e (4U(i:pik ~ 8^8X1^SX a03^1^T13\ T? Bz3T! #\oK |J,vv ]|#AxD#AL PUF i5$5p_5$__ P@I%9Xn%fc P/e v~-vqe. s;6Y;a; HD 3]Jc WSnklVp t@ ejZ5tZ }+9#!TSb!+T 0Mgr;8M\0 mRK{/ A] EE1I E!0_ * mGp4W4fU$( aBX ho)p(5M |ZwjEs ,b gCjgp] 4]esLce[.

Mc:\cdP#
|9go1go iAD! 3/ |rXr:1^_
WSw8%
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
=mFQm
280?~ao?f8z
`) 3M~M
280?~ao?f8z
p2 gCzC+*+
280?~ao?f8z
g~d~PgP
280?~ao?f8z
LC h*|*
280?~ao?f8z
Yu }k& {2t$70 ACbz
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
h6NQVrCQw 3S
280?~ao?f8z
&( r3@p? wig
280?~ao?f8z
bs {q(}H N*w
280?~ao?f8z
yZ JR]c]
280?~ao?f8z
ei+]d3O B_J^J
280?~ao?f8z
4Vl 7-d%d
280?~ao?f8z
$@ +Ad\\
280?~ao?f8z
699I=D=
280?~ao?f8z
V% K\TT
280?~ao?f8z
W&N9u Pse^!#
280?~ao?f8z
bK !6? k%b|v 0qX+b#
280?~ao?f8z
bK !6? k%b|v 0qX+b#
280?~ao?f8z
bK !6? k%b|v 0qX+b#
280?~ao?f8z
,u tXXxE av*^*
280?~ao?f8z
E5 Ld q)qUq
280?~ao?f8z
_X~g [11J1
280?~ao?f8z
ei+]d3O B_J^J
280?~ao?f8z
p2 gCzC+*+
280?~ao?f8z
V% K\TT
280?~ao?f8z
&r Djuu
280?~ao?f8z
}8 z6``
280?~ao?f8z
cH @W%@(4W
280?~ao?f8z
bY UlT
280?~ao?f8z
j\ dmm
280?~ao?f8z
Ko Oa|
280?~ao?f8z
JejE 2aa
280?~ao?f8z
-T ADKIK d|HiVHzZliRH| k($_:);nm(z%
280?~ao?f8z
@a]]:By]q iMi LdXAcc
280?~ao?f8z
_qqyyDPD#! oI)TE $HSwSDDS6$7H
280?~ao?f8z
J&PzT&z 0:0dA0[=$W %n1&sH1wZ&%
280?~ao?f8z
G-@-? hGR|KS3SH
280?~ao?f8z
)[) Fg=
280?~ao?f8z
bMYG11 Z`[SyH`HAS$e
280?~ao?f8z
bMYG11 Z`[SyH`HAS$e
280?~ao?f8z
p~+]++ Bz~/sxzx_/%s;
280?~ao?f8z
@m@ psc m%W %|% e@@
280?~ao?f8z
6W s\\ᵃ
280?~ao?f8z
]L] gP
280?~ao?f8z
b&b zjj
280?~ao?f8z
383 C-|
280?~ao?f8z
wN #aaT\aaD
280?~ao?f8z
WtW == wSg) HTnnSn?Q
280?~ao?f8z
9ywyyq!
280?~ao?f8z
bMYG11 Z`[SyH`HAS$e
280?~ao?f8z
&))T-))
280?~ao?f8z
$&
280?~ao?f8z
lul Xj
280?~ao?f8z
{g{ ,,|
280?~ao?f8z
Hv )A;
280?~ao?f8z
383 C-|
280?~ao?f8z
ddd (J]KJ ;R{# ~uWSP
280?~ao?f8z
!rs:NFenwU z-hJzhU d5*,-- aj0U],j,&U?y

J{ GP &|e|yU +)+/

\Amgen collaboration; BeiGene has China commercial rights. ~Ensem collaboration; BeiGene has global rights. ]DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 9Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. ?Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. AAmgen collaboration; BeiGene has development and commercialization rights in China. 2In combination with Zanubrutinib. \May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login